Dyslipidemia Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028

Published on : Feb-2019 | List of Tables : 33 | List of Figures : 141 | No. of Pages : 170 | Report Code : FACT2928MR | Format : ppt pdf Excel Word

Consolidation of Multinationals Continues, With Nearly 60% Shares

Nature of the global dyslipidemia therapeutics market remains consolidated, with leading players accounting for approximately 60% shares. Co-promotion of dyslipidemia therapeutic drugs with local or regional players, aggressive marketing, new product launches, and high investments in research and development of novel drugs are the go-to strategies being employed by leading dyslipidemia therapeutics market players to expand their global footprint. Meanwhile, local players continue to focus on expanding their manufacturing capacity to meet the growing demand for dyslipidemia drugs in the regional market. Additionally patent expiration of a multiple dyslipidemia drugs is expected to open up new opportunities for the regional players in terms of drug discovery and development. Some of the notable highlights of the dyslipidemia therapeutics market have been listed below:

  • To capitalize on the growing demand for dyslipidemia drugs in the Chinese market, AstraZeneca entered into a strategic alliance with Luye Pharma that bestowed the company with exclusive rights to promote Lyue Pharma’s Xuezhikang Capsules - a drug that has been identified as the first-line blood management medication by the Chinese government.
  • As a part of its marketing strategy, Kowa Pharmaceuticals America, Inc. launched the “Take Cholesterol to Heart” campaign, to promote the efficacy of statins in the treatment of dyslipidemia. The company is partnering with Hollywood stars and TV actors for the campaign.
  • Sanofi, a French pharmaceutical company launched Praluent, a novel dyslipidemia therapy in Korea in collaboration with Aventis Korea. This new therapy will work towards inhibiting the binding of PCSK9 to low-density lipoprotein receptors (LDLRs).
  • In January 2019, Amgen received approval for its proprietary drug Repatha from the National Medical Products Administration (NMPA) in China. The drug will be the first PCSK9 inhibitor medication for adults in China where the prevalence of dyslipidemia has increased in the recent past, triggering the demand for dyslipidemia therapeutics in the region.
  • Recent research has linked the presence of high levels of lipoprotein (a) cholesterol (Lp[a]-C), and low levels of lipoprotein cholesterol subparticle 3 (HDL3C), identifying these as novel biomarkers to diagnose the severity of coronary artery disease (CAD) in patients. The results have the potential to drive advancements in the dyslipidemia therapeutics market.

The report on the dyslipidemia therapeutics market also provides a detailed analysis of the key players operating in the dyslipidemia therapeutics market. The dyslipidemia therapeutics market report provides a comprehensive profile of leading players functioning in the dyslipidemia therapeutics market which include Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, and Novartis AG.

For full coverage of the competitive landscape, get in touch with our experts

dyslipidemia therapeutics market forecast & y o y growth

Efficacy-driven Novel Approaches for Dyslipidemia Therapeutics

Combination therapies for dyslipidemia have gained a marked significance in the recent past, deemed as an efficient solution to offset concerns regarding varied effectiveness of statins with respect to affected patients. Complementary mechanisms in combination with statins have emerged as a novel measures to ebb low-density lipoprotein levels – a key aspect enhancing the risk of dyslipidemia. Recent approval of novel drugs such as PCSK9 antibodies by regulatory authorities such as China’s National Medical Products Administration (NMPA), and The UK’s National Institute for Health and Care Excellence (NICE), alludes a rise in prevalence of novel drugs for dyslipidemia therapeutics in the near future. Medical researchers’ efforts towards the identification of new gene therapies for treatment of Mendelian lipid disorders can further open gateways to efficient dyslipidemia therapeutics and management. Additionally, leading players in the dyslipidemia therapeutics market are taking efforts to improve the overall efficacy of their dyslipidemia therapeutic drugs and are investing heavily in research and development of novel medication to target triglycerides and other lipoproteins.

For detailed analysis on all the key market factors, request a sample

Opportunities Imminent for Players, as Use of Nutraceuticals in Dyslipidemia Therapeutics Gains Significance

Shifting consumer preference towards using nutraceuticals to combat health concerns has triggered multiple researches on effectiveness of nutraceuticals in reducing lipid levels in patients. Statin intolerance is a common occurrence in patients, and nutraceuticals provide a natural alternative to keep lipids in check. Consumption of statins has been linked with certain side effects that has significantly raised concerns regarding statins among healthcare professionals and patients alike. New-onset diabetes, muscle pain, and increased incidences of hemorrhagic stroke have been reported among patients consuming statins. Nutraceuticals such has omega-3 fatty acids, soy proteins, spirulina, lupin, berberine, red yeast rice, and garlic fibers are some of the functional foods that have cholesterol-lowering benefits. Although the degree of their effectiveness on different patients is not yet fully understood, nutraceuticals are likely to gain significance as a natural treatment with no adverse effects on patients.

Collaborative and Integrated Efforts towards Drug Development to be a Key Growth Influencer

With growth palpability in patent expiration of multiple exclusive dyslipidemia therapeutic drug, pharmaceutical companies are continuously striving towards developing new and innovative solutions. However, certain factors such as lower pricing pressures, and early access to new and innovative therapies, have exacerbated the difficulties in drug development for dyslipidemia therapeutics. This has further resulted in a significant imbalance between R&D investments and profits related to dyslipidemia therapeutics.

Pharmaceutical companies are already following strategies such as open innovation, in-and-out licensing, and active technology scouting to boost innovation in dyslipidemia therapeutics development. Additionally, agency partners that offer a multidisciplinary and integrated approach for drug development will continue to sustain growth of the dyslipidemia therapeutics market. With expertise across disciplines, the agency partners could provide a solution to streamline the process of new drug development and marketing thus simplifying the drug development process for pharmaceutical companies.

Government Initiatives Aimed at Dyslipidemia Awareness to Uphold Growth

According to a report by the World Health Organization (WHO) ischemic heart diseases were identified as the leading cause of deaths around the world, accounting for 15.2 million deaths in 2016. Dyslipidemia has been associated with significant risk of ischemic heart diseases, strokes, heart attacks, and other cardiovascular conditions. Another report from WHO stated that dyslipidemia was responsible for causing 2.6 million deaths and 29.7 million disability adjusted life years. The adverse impact of the condition has prompted governments to initiate awareness campaigns and provide a proliferating environment for the development and approval of dyslipidemia therapeutics. For instance, the American College of Cardiology and American Heart Association released updated guidelines on cholesterol in November 2018 educating the population about personalized risk assessments of higher cholesterol levels and listed a set of recommended dyslipidemia therapeutic drugs. Along the same lines, UK Health Ministry ordered the rapid uptake of the newly discovered PCSK9 inhibitors with an aim to enable the beneficial treatment to reach patients quickly. The amiable environment created by regulatory authorities around the world is expected to fuel the dyslipidemia therapeutics market growth.    

Dyslipidemia Therapeutics Market - Definition

Dyslipidemia is a condition caused due to the presence of an abnormal amount of lipids such as triglycerides, fat phospholipids, and cholesterol in the blood. The presence of these lipids increases the chances of stroke, heart attacks, atherosclerosis, and other circulatory problems. Therapies and drugs used in the treatment of dyslipidemia are termed as dyslipidemia therapeutics which includes drugs such as statins, non-statins, fibrates, inhibitors, and bile acid resins.

Dyslipidemia Therapeutics Market - About the report

The report on dyslipidemia therapeutics market offers comprehensive insights into the dyslipidemia therapeutics market. The FactMR dyslipidemia market report provides a thorough assessment of the dyslipidemia market facets such as drivers, restraints, trends, opportunities, challenges, and threats.

The dyslipidemia therapeutics market report provides an accurate forecast of the dyslipidemia therapeutics market which is meant to aid stakeholders and business professionals in streamlining their strategies to obtain maximum profitability.

Dyslipidemia Therapeutics Market – Segmentation

The dyslipidemia therapeutics market report offers a detailed analysis of the dyslipidemia market on the basis of different segments. A comprehensive analysis of each of the dyslipidemia therapeutics market segments on the basis of value, Y-o-Y growth, revenue share, and CAGR has been provided in the report.

The dyslipidemia therapeutics market has been segmented on the basis of drug class, distribution channel, type, and region.

dyslipidemia therapeutics taxonomy

Dyslipidemia Therapeutics Market – Additional Questions Answered

Apart from the aforementioned insights about the dyslipidemia therapeutics market, the report answers the following questions related to dyslipidemia therapeutics market:

  • What region will hold the largest share of the dyslipidemia therapeutics market in 2019?
  • What dyslipidemia drug type currently holds the pole position in terms of revenue?
  • What dyslipidemia drug class will register the highest sales in 2019?
  • What sales channel accounted for the most dyslipidemia therapeutic drug sales in 2018?
  • What are the lucrative opportunities on offer in the dyslipidemia therapeutics market?

Dyslipidemia Therapeutics Market – Research Methodology

The key insights propounded in the dyslipidemia therapeutics market report are a consequence of thorough research. A comprehensive two-step research process was employed to survey all the aspects pertaining to the dyslipidemia therapeutics market. The report on dyslipidemia therapeutics market is a combination of detailed primary and secondary researches performed by the analysts at Fact.MR.

Results from both the phases of research were triangulated to produce an accurate and authentic forecast of the dyslipidemia therapeutics market.

Request methodology of this report.

A recently compiled Fact.MR report, titled “Dyslipidemia Therapeutics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2018-2028” provides a comprehensive analysis of the dyslipidemia therapeutics market. Size of the dyslipidemia therapeutics market has been analyzed during the forecast period of 2018-2028 and has been propounded in terms of value has been provided in the report. The report also provides a detailed analysis and forecast of the dyslipidemia therapeutics market.

Chapter 1 – Executive Summary

 The dyslipidemia therapeutics market report commences with an executive summary of the dyslipidemia therapeutics market which provides brief yet affluent information about the market along with exclusive recommendations by Fact.MR and a thorough analysis of the dyslipidemia therapeutics market.

Chapter 2 – Market Introduction

 The chapter provides a clear definition of the dyslipidemia therapeutics market along with the segments the dyslipidemia therapeutics market is divided into.

Chapter 3 – Market Dynamics

The section lists the trends, drivers, challenges, and opportunities prevalent in the dyslipidemia therapeutics market. Each of the dyslipidemia therapeutics market aspect enlisted under the chapter has been thoroughly analyzed and impact analysis of each them is provided under this chapter. In addition to this, the macroeconomic factors that hold influence over the dyslipidemia therapeutics market have been enlisted.

Chapter 4 – Global Dyslipidemia Therapeutics Market Analysis and Forecast

The chapter commences with an overview of the global dyslipidemia therapeutics market and provides a valuable analysis of the average pricing around the world coupled with a detailed region-wise demand assessment. The section further provides a detailed analysis of the dyslipidemia therapeutics market on the basis of drug type, class, and distribution channel.

Chapter 5 – North America Dyslipidemia Therapeutics Market Analysis

The chapter commences with an overview of the dyslipidemia therapeutics market and then evaluates the market in the region on the basis of country, drug type, class, and distribution channel. A comparative analysis of each of the segments on the basis of Y-o-Y growth and market share has been provided in the report.

Chapter 6 – Latin America Dyslipidemia Therapeutics Market Analysis

Under this section, a detailed analysis of the dyslipidemia therapeutics market existent in the Latin American region has been provided. A comprehensive analysis of the market on the basis of country, drug type, drug class, and distribution channel has been provided. The report also provides a comparative analysis of the categories identified under each of the segments.

Chapter 7 – Europe Dyslipidemia Therapeutics Market Analysis

The chapter commences with an introduction of the dyslipidemia therapeutics market. The ensuing segments of the chapter provide a detailed analysis of the dyslipidemia therapeutics market, as well as a comprehensive forecast of the market on the basis of drug type, drug class, distribution channel, and country.

Chapter 8 – CIS & Russia Dyslipidemia Therapeutics Market Analysis

The chapter commences with an introduction to the dyslipidemia therapeutics market in Russia. The subsequent sections of the chapter provide a detailed analysis and forecast of the dyslipidemia therapeutics market on the basis of country, drug type, drug class, and distribution channel.

Chapter 9 – Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis

The chapter begins with an overview of the dyslipidemia therapeutics market existent in the Asia Pacific Excluding Japan & China region. The ensuing segments of the report provide a detailed assessment and forecast of the dyslipidemia therapeutics market in the region on the basis of country, drug class, drug type, and distribution challenge.

Chapter 10 – China Dyslipidemia Therapeutics Market Analysis

Under this chapter, a thorough overview of the dyslipidemia therapeutics market existent in China has been provided along with a comprehensive forecast of the dyslipidemia therapeutics market on the basis of drug class, drug type, and distribution channel. Each of the segments identified has been presented on the basis of value and Y-o-Y growth.

Chapter 11 – Japan Dyslipidemia Therapeutics Market Analysis

A thorough analysis of the overall market in Japan has been provided under this section. The ensuing sections of the chapter provide a detailed market breakdown on the basis of drug type, drug class, and distribution channel. A comparative analysis under each of the segments has been provided in terms of revenue share and Y-o-Y growth.

Chapter 12 – MEA Dyslipidemia Therapeutics Market Analysis

The chapter provides a detailed analysis of the dyslipidemia therapeutics market existent in the MEA region. A thorough analysis in addition to an elaborate forecast of the dyslipidemia therapeutics market on the basis of drug type, country, drug class, and distribution channel has been provided under the report.

Chapter 13 – Competitive Assessment

The chapter provides a detailed analysis of the level of competitiveness prevalent in the market. A dashboard view of all the key market players along with the breakdown of the market on the basis of revenue share has been provided under this chapter.

Chapter 14 – Company Profiles

All the leading players operating in the dyslipidemia therapeutics market have been enlisted under this section. Further, detailed profiling of each of the players sheds light on their strengths, weaknesses, market presence, global footing, revenue share, and other notable business developments. The chapter provides valuable information that can help stakeholders and business professionals streamline their strategies to gain maximum profitability.

Chapter 15 – Assumptions and Acronyms Used

The chapter lists all the assumptions considered during the compilation of the report. All the acronyms used in the report have been listed in the chapter to help readers gain a better understanding of the information presented in the report.

Chapter 16 – Research Methodology

The robust and elaborate research methodology employed during the compilation of the report has been explained under the section. A two-phase research process involving primary and secondary researches was used to uncover all the insights and figures presented in the report. While the primary research phase involved rigorous interviews with industry savants, secondary research was conducted by thoroughly studying company press releases, trade journals, paid sources, and other industry-related publications. Results from both the steps of the research were triangulated to create an accurate and authentic forecast of the dyslipidemia therapeutics market.

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FACT.MR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Introduction
2.2. Market Definition
2.3. Market Taxonomy

3. Market Dynamics
3.1. Growth Drivers and Impact Analysis
3.2. Industry Challenges and Impact Analysis 
3.3. Industry trends and Impact analysis
3.4. Opportunity Assessment in Dyslipidemia Therapeutics Market
3.5. Macro - Economic Factors influencing demand
3.6. PESTEL Analysis

4. Global Dyslipidemia Therapeutics Market Analysis and Forecast
4.1. Global Dyslipidemia Therapeutics Market Outlook
       4.1.1. Market Value (US$ Mn) Forecast and Analysis
       4.1.2. Price Index and Price Point Assessment, by key Products
       4.1.3. Regional Demand Assessment
                4.1.3.1. Market Value Share by Region
4.2. Global Dyslipidemia Therapeutics Market Analysis by Type
       4.2.1. Low-density Lipoproteins (LDL)
       4.2.2. Triglycerides 
4.3. Dyslipidemia Therapeutics Market Analysis by Drug Class
       4.3.1. Statins
       4.3.2. Non-Statins
                4.3.2.1. PCSK9 inhibitors
                4.3.2.2. Cholesterol absorption inhibitors
                4.3.2.3. Bile Acid resins
                4.3.2.4. Fibrate
                4.3.2.5. Others
       4.3.3. Combinations Drugs
4.4. Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       4.4.1. Hospitals Pharmacies
       4.4.2. Drug Stores
       4.4.3. Retail Stores
       4.4.4. Mail Order Pharmacies 

5. North America Dyslipidemia Therapeutics Market Analysis
5.1. Introduction
       5.1.1. North America Business Outlook 
       5.1.2. North America Dyslipidemia Therapeutics Market Outlook
5.2. North America Dyslipidemia Therapeutics Market Outlook
       5.2.1. Market Value (US$ Mn) Forecast and Analysis
       5.2.2. Country Wise Demand Assessment
                5.2.2.1. US Market Value Share
                5.2.2.2. Canada Market Value Share
5.3. North America Dyslipidemia Therapeutics Market Analysis by Product Type
       5.3.1. Value (US$ Mn) Forecast by Type
       5.3.2. Y-o-Y Growth Comparison by Type 
5.4. North America Dyslipidemia Therapeutics Market Analysis by Drug Class
       5.4.1. Value (US$ Mn) Forecast by Drug Class
       5.4.2. Y-o-Y Growth Comparison by Drug Class 
5.5. North America Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       5.5.1. Value (US$ Mn) Forecast by Distribution Channel
       5.5.2. Y-o-Y Growth Comparison by Distribution Channel
5.6. Market Attractiveness Analysis

6. Latin America Dyslipidemia Therapeutics Market Analysis 
6.1. Introduction
       6.1.1. Latin America Business Outlook 
       6.1.2. Latin America Dyslipidemia Therapeutics Market Outlook
6.2. Latin America Dyslipidemia Therapeutics Market Outlook
       6.2.1. Value (US$ Mn) Forecast and Analysis
       6.2.2. Country Wise Demand Assessment
                6.2.2.1. Brazil Market Value Share
                6.2.2.2. Mexico Market Value Share 
                6.2.2.3. Rest of LA Market Value Share 
6.3. Latin America Dyslipidemia Therapeutics Market Analysis by Type
       6.3.1. Value (US$ Mn) Forecast by Type
       6.3.2. Y-o-Y Growth Comparison by Type
6.4. Latin America Dyslipidemia Therapeutics Market Analysis by Drug Class 
       6.4.1. Value (US$ Mn) Forecast by Drug Class 
       6.4.2. Y-o-Y Growth Comparison by Drug Class 
6.5. Latin America Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       6.5.1. Value (US$ Mn) Forecast by Distribution Channel
       6.5.2. Y-o-Y Growth Comparison by Distribution Channel
6.6. Market Attractiveness Analysis

7. Europe Dyslipidemia Therapeutics Market Analysis
7.1. Introduction
       7.1.1. Europe Business Outlook 
       7.1.2. Europe Dyslipidemia Therapeutics Market Outlook
7.2. Europe Dyslipidemia Therapeutics Market Outlook
       7.2.1. Value (US$ Mn) Forecast and Analysis
       7.2.2. Country Wise Demand Assessment
                7.2.2.1. Germany Market Value Share
                7.2.2.2. UK Market Value Share 
                7.2.2.3. France Market Value Share
                7.2.2.4. Spain Market Value Share 
                7.2.2.5. Italy Market Value Share
                7.2.2.6. Rest of Europe Market Value Share 
7.3. Europe Dyslipidemia Therapeutics Market Analysis by Type
       7.3.1. Value (US$ Mn) Forecast by Type
       7.3.2. Y-o-Y Growth Comparison by Type
7.4. Europe Dyslipidemia Therapeutics Market Analysis by Drug Class 
       7.4.1. Value (US$ Mn) Forecast by Drug Class 
       7.4.2. Y-o-Y Growth Comparison by Drug Class 
7.5. Europe Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       7.5.1. Value (US$ Mn) Forecast by Distribution Channel
       7.5.2. Y-o-Y Growth Comparison by Distribution Channel
7.6. Market Attractiveness Analysis

8. CIS & Russia Dyslipidemia Therapeutics Market Analysis
8.1. Introduction
       8.1.1. CIS & Russia. Business Outlook 
       8.1.2. CIS & Russia Dyslipidemia Therapeutics Market Outlook
8.2. CIS & Russia Dyslipidemia Therapeutics Market Outlook
       8.2.1. Market Value (US$ Mn) Forecast and Analysis
8.3. CIS & Russia Dyslipidemia Therapeutics Market Analysis by Type
       8.3.1. Value (US$ Mn) Forecast by Type
       8.3.2. Y-o-Y Growth Comparison by Type 
8.4. CIS & Russia Dyslipidemia Therapeutics Market Analysis by Drug Class 
       8.4.1. Value (US$ Mn) Forecast by Drug Class 
       8.4.2. Y-o-Y Growth Comparison by Drug Class 
8.5. CIS & Russia Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       8.5.1. Value (US$ Mn) Forecast by Distribution Channel
       8.5.2. Y-o-Y Growth Comparison by Distribution Channel
8.6. Market Attractiveness Analysis

9. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis
9.1. Introduction
       9.1.1. Asia Pacific Excluding Japan & China Business Outlook 
       9.1.2. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Outlook
9.2. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Outlook
       9.2.1. Value (US$ Mn), Forecast and Analysis
       9.2.2. Country Wise Demand Assessment
                9.2.2.1. India Market Value Share 
                9.2.2.2. Australia & New Zealand Market Value Share
                9.2.2.3. Rest of APEJC Market Value Share 
9.3. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis by Type
       9.3.1. Value (US$ Mn) Forecast by Type
       9.3.2. Y-o-Y Growth Comparison by Type 
9.4. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis by Drug Class 
       9.4.1. Value (US$ Mn) Forecast by Drug Class 
       9.4.2. Y-o-Y Growth Comparison by Drug Class 
9.5. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       9.5.1. Value (US$ Mn) Forecast by Distribution Channel
       9.5.2. Y-o-Y Growth Comparison by Distribution Channel
9.6. Market Attractiveness Analysis

10. China Dyslipidemia Therapeutics Market Analysis
10.1. Introduction
       10.1.1. China Business Outlook 
       10.1.2. China Dyslipidemia Therapeutics Market Outlook
10.2. China Dyslipidemia Therapeutics Market Outlook
       10.2.1. Market Value (US$ Mn) Forecast and Analysis
10.3. China Dyslipidemia Therapeutics Market Analysis by Type
       10.3.1. Value (US$ Mn) Forecast by Type
       10.3.2. Y-o-Y Growth Comparison by Type 
10.4. China Dyslipidemia Therapeutics Market Analysis by Drug Class 
       10.4.1. Value (US$ Mn) Forecast by Drug Class 
       10.4.2. Y-o-Y Growth Comparison by Drug Class 
10.5. China Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       10.5.1. Value (US$ Mn) Forecast by Distribution Channel
       10.5.2. Y-o-Y Growth Comparison by Distribution Channel
10.6. Market Attractiveness Analysis

11. Japan Dyslipidemia Therapeutics Market Analysis
11.1. Introduction
       11.1.1. Japan Business Outlook 
       11.1.2. Japan Dyslipidemia Therapeutics Market Outlook
11.2. Japan Dyslipidemia Therapeutics Market Outlook
       11.2.1. Market Value (US$ Mn) Forecast and Analysis
11.3. Japan Dyslipidemia Therapeutics Market Analysis by Type
       11.3.1. Value (US$ Mn) Forecast by Type
       11.3.2. Y-o-Y Growth Comparison by Type 
11.4. Japan Dyslipidemia Therapeutics Market Analysis by Drug Class 
       11.4.1. Value (US$ Mn) Forecast by Drug Class 
       11.4.2. Y-o-Y Growth Comparison by Drug Class 
11.5. Japan Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       11.5.1. Value (US$ Mn) Forecast by Distribution Channel
       11.5.2. Y-o-Y Growth Comparison by Distribution Channel
11.6. Market Attractiveness Analysis

12. MEA Dyslipidemia Therapeutics Market Analysis
12.1. Introduction
       12.1.1. MEA Business Outlook 
       12.1.2. MEA Dyslipidemia Therapeutics Market Outlook
12.2. MEA Dyslipidemia Therapeutics Market Outlook
       12.2.1. Value (US$ Mn) Forecast and Analysis
       12.2.2. Country Wise Demand Assessment
                12.2.2.1. GCC Countries Market Value Share
                12.2.2.2. South Africa Market Value Share
                12.2.2.3. Rest of MEA Market Value Share 
12.3. MEA Dyslipidemia Therapeutics Market Analysis by Type
       12.3.1. Value (US$ Mn) Forecast by Type
       12.3.2. Y-o-Y Growth Comparison by Type
12.4. MEA Dyslipidemia Therapeutics Market Analysis by Drug Class
       12.4.1. Value (US$ Mn) Forecast by Drug Class 
       12.4.2. Y-o-Y Growth Comparison by Drug Class 
12.5. MEA Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       12.5.1. Value (US$ Mn) Forecast by Distribution Channel
       12.5.2. Y-o-Y Growth Comparison by Distribution Channel
12.6. Market Attractiveness Analysis

13. Competitive Assessment
13.1. Dyslipidemia Therapeutics Market Competition - a Dashboard View
13.2. Dyslipidemia Therapeutics Market Structure, By Tier

14. Company Profiles
14.1. AstraZeneca 
       14.1.1. Company Overview
       14.1.2. Key Developments
       14.1.3. Segment Financials
       14.1.4. Product Portfolio
       14.1.5. Key Strategies
14.2. Kowa Pharmaceuticals America, Inc. 
       14.2.1. Company Overview
       14.2.2. Key Developments
       14.2.3. Segment Financials
       14.2.4. Product Portfolio
       14.2.5. Key Strategies
14.3. Merck & Co. 
       14.3.1. Company Overview
       14.3.2. Key Developments
       14.3.3. Segment Financials
       14.3.4. Product Portfolio
       14.3.5. Key Strategies
14.4. Pfizer
       14.4.1. Company Overview
       14.4.2. Company Overview
       14.4.3. Key Developments
       14.4.4. Segment Financials
       14.4.5. Product Portfolio
       14.4.6. Key Strategies
14.5. Sanofi
       14.5.1. Company Overview
       14.5.2. Key Developments
       14.5.3. Segment Financials
       14.5.4. Product Portfolio
       14.5.5. Key Strategies
14.6. Amgen
       14.6.1. Company Overview
       14.6.2. Key Developments
       14.6.3. Segment Financials
       14.6.4. Product Portfolio
       14.6.5. Key Strategies
14.7. Novelion Therapeutics 
       14.7.1. Company Overview
       14.7.2. Key Developments
       14.7.3. Segment Financials
       14.7.4. Product Portfolio
       14.7.5. Key Strategies
14.8. Mylan
       14.8.1. Company Overview
       14.8.2. Key Developments
       14.8.3. Segment Financials
       14.8.4. Product Portfolio
       14.8.5. Key Strategies
14.9. Abbott Laboratories
       14.9.1. Company Overview
       14.9.2. Key Developments
       14.9.3. Segment Financials
       14.9.4. Product Portfolio
       14.9.5. Key Strategies
14.10. Novartis AG
       14.10.1. Company Overview
       14.10.2. Key Developments
       14.10.3. Segment Financials
       14.10.4. Product Portfolio
       14.10.5. Key Strategies

15. Assumptions and Acronyms Used

16. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Dyslipidemia Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028